Skip to Content

Generic Carnitor SF Availability

See also: Generic Carnitor

Carnitor SF is a brand name of levocarnitine, approved by the FDA in the following formulation(s):

CARNITOR SF (levocarnitine - solution;oral)

  • Manufacturer: LEADIANT BIOSCI INC
    Approval date: March 28, 2007
    Strength(s): 1GM/10ML [AA]

Has a generic version of Carnitor SF been approved?

Yes. The following products are equivalent to Carnitor SF:

levocarnitine solution;oral

  • Manufacturer: HI TECH PHARMA
    Approval date: October 25, 2007
    Strength(s): 1GM/10ML [AA]
  • Manufacturer: LYNE
    Approval date: August 10, 2004
    Strength(s): 1GM/10ML [AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Carnitor SF. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.


Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
AAProducts in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved.